BASEL, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions. This acquisition, first announced in January 2024, marks another significant milestone in Bruker’s expansion in vendor-agnostic scientific software, R&D and QC digitalization, and laboratory automation – altogether an important initiative within Bruker’s strategic P ...

Bruker Corporation (BRKR) recently entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of the pre-eminent private equity firm PAI Partners, to acquire ELITechGroup. However, the €870 million cash transaction excludes the carved-out ELITech clinical chemistry business.The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals, the carve-out of the clinical chemistry business and other customary closing conditions. Upon closi ...

BRUKER CORPORATION ANNUAL REPORT ON FORM 10-K TABLE OF CONTENTS Part III Item 10 Directors, Executive Officers and Corporate Governance 111 Item 11 Executive Compensation 111 Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 111 Item 13 Certain Relationships and Related Transactions, and Director Independence 111 Item 14 Principal Accountant Fees and Services 111 ITEM 1 BUSINESS BSI BioSpin Segment The BSI BioSpin Segment also offers a range of services, ...

Bruker (BRKR) continues to grow driven by its fundamental commitment to innovate high-value solutions and the ongoing portfolio transformation. However, Bruker’s operations face the downside of excessive currency exposure. The stock carries a Zacks Rank #3 (Hold) currently.Bruker’s CALID Group has been making decent progress lately, primarily because of the strong demand for differentiated instruments. The group is benefiting from sustained growth in the mass spectrometry business, including the FT-IR, Near ...

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Citi 2024 Unplugged Medtech and Life Sciences Access Day in New York City Thursday, February 29, 2024, at 8:45 a.m. Eastern Time TD Cowen 44th Annual Health Care Conference in Boston, MA Monday, March 4, 2024, at 9:50 a.m. Eastern Time Live audiovisual webcasts of the presentations will be avail ...

The Zacks Instruments - Scientific industry is benefiting from increasing healthcare spending, driven by an aging demography, and continued innovation in the pharma and life sciences end-markets. Higher demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Industry participants like Mettler-Toledo International (MTD) and Bruker (BRKR) are gaining from the growing testing needs of newer biological drugs. Increased scrutiny of per and polyfluoroalkyl substance ...

The Nasdaq is off to a scorching start in 2024. The Nasdaq 100 Index is making new highs seemingly almost every week, and glamor stocks in fields such as artificial intelligence (AI) and semiconductors are blasting off.This has left some investors worried about a potential bubble. There are definitely some significantly overvalued Nasdaq stocks out there. However, there are still quite a few good buys within the Nasdaq today. These three Nasdaq stocks to buy, in particular, offer good entry points right now ...

Bruker Corporation (BRKR) delivered adjusted earnings per share (EPS) of 70 cents in the fourth quarter of 2023, down 5.4% year over year. The figure exceeded the Zacks Consensus Estimate by 7.7%.The adjustments include expenses related to the amortization of purchased intangibles, acquisition-related costs and restructuring costs, among others.GAAP EPS in the quarter was $1.41, surging 113.6% from the year-earlier quarter’s figure of 66 cents.For the full year, adjusted earnings were $2.58 per share, risin ...

Financial Data and Key Metrics Changes - In Q4 2023, Bruker reported revenues of $854.5 million, a 20.6% increase year-over-year, with organic revenue growth of 15.9% [9][54] - For the full year 2023, revenues increased by 17.1% to $2.96 billion, with organic growth of 14.5% [11][34] - Non-GAAP diluted EPS for Q4 2023 was $0.70, down 5.4% from $0.74 in Q4 2022, primarily due to the PhenomeX acquisition [10][59] - The company achieved a non-GAAP EPS growth of 10.3% year-over-year for 2023 [8][48] Business Line Data and Key Metrics Changes - The Scientific Instruments segment (BSI) saw 15.5% organic growth, while the best segment experienced 20.3% organic growth in Q4 2023 [9] - BioSpin Group revenue for 2023 was $799 million, growing in the teens percentage range [24] - Bruker Nano revenue reached $942 million in 2023, with high teens percentage growth [25] - The CALID group had revenue of $960 million, with strong growth driven by life science mass spectrometry [50] Market Data and Key Metrics Changes - In Q4 2023, Americas revenue grew in the teens percentage, Asia-Pacific revenue grew in the 20% range, and European revenue grew in the mid-teens percentage [32] - The EMEA region reported high single-digit percentage revenue growth year-over-year in Q4 2023 [32] Company Strategy and Development Direction - Bruker aims to achieve its fiscal year 2026 medium-term outlook for revenue and non-GAAP EPS by fiscal year 2025, driven by strong growth and strategic acquisitions [15][37] - The company is focusing on innovation in high-value solutions and ongoing portfolio transformation [27][53] - Recent acquisitions, including PhenomeX, are expected to enhance Bruker's capabilities in the post-genomic era [14][115] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2024, expecting organic revenue growth of 5% to 7% and non-GAAP EPS growth of 5% to 7% compared to 2023 [21][35] - The company noted that geopolitical risks, particularly related to conflicts, could impact operations but emphasized strong fundamentals in the academic and government sectors [18][117] - Management highlighted a solid backlog and bookings momentum entering 2024, indicating a positive outlook for continued growth [21][131] Other Important Information - Bruker reported a non-GAAP operating margin of 18.1% in Q4 2023, down 290 basis points year-over-year due to acquisition headwinds [58] - The company generated $205.5 million of operating cash flow in Q4 2023, with free cash flow of $174 million [57][60] - The effective tax rate for Q4 2023 was 31.3%, compared to 20.6% in the prior year [33] Q&A Session Summary Question: Can you discuss the LRP pull-forward comment and its implications for earnings growth? - Management expressed optimism about pulling forward revenue and non-GAAP EPS targets due to strong 2023 results and execution, with expectations for significant EPS growth in 2025 [39] Question: Can you unpack the margin guidance and the factors affecting it? - Management clarified that the margin guidance is impacted by the timing of the PhenomeX acquisition, which will become a tailwind in future periods [43] Question: What is the outlook for the academic market given current geopolitical conditions? - Management noted that academic government revenue growth remains strong, with solid bookings growth, despite some fluctuations in specific regions like China [68] Question: How are the recent acquisitions expected to impact profitability? - Management indicated that the recent acquisitions are profitable and will not significantly impact margins negatively [139] Question: What is the current status of backlog and its implications for future growth? - Management reported a backlog of approximately 7.5 months, which is elevated but expected to decrease over the next few years [131]

Bruker (BRKR) reported $854.5 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 20.6%. EPS of $0.70 for the same period compares to $0.74 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $830.68 million, representing a surprise of +2.87%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being $0.65.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...